Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sangamo Therapeutics excels in 2022 trials, prioritizes innovative programs

Sangamo Therapeutics had a strong year in 2022, focusing on key programs like CAR-Treg and Fabry disease while making strategic decisions to optimize resources.
Positive trial results and FDA alignment signal progress and potential for future collaborations and advancements in treatments.
Challenges include resource reallocation, endpoint validation, and data transparency, which require careful management and strategic planning.
Overall, Sangamo's performance, strengths, and opportunities position the company well for continued growth and innovation in the biopharmaceutical sector.

Sangamo Therapeutics reports strong Q1 revenue and strategic reorganization

Sangamo Therapeutics is strategically reorganizing to focus on neurology, Fabry, and TX200 CAR-Treg programs, aiming to reduce cash burn and enhance operational efficiency.
The company's emphasis on genomic medicines for chronic pain and neurological disorders highlights its commitment to addressing significant unmet medical needs.
While facing capital constraints, Sangamo is exploring financing options and partnerships to support future growth and innovation, balancing patient benefit and safety in clinical advancements.

Sangamo Therapeutics excels in clinical progress and strategic collaborations

Sangamo Therapeutics demonstrates strong performance in clinical and preclinical programs, backed by a solid financial position and strategic collaborations. Challenges include the need for additional funding and ensuring successful trial execution. Opportunities for growth through expanding partnerships and innovative genomic engineering approaches.

Sangamo shifts focus to neurology, eyes partnerships for growth

Sangamo's strategic shift to neurology shows promise but requires navigating challenges of restructuring and resource reallocation.
The company's financial discipline and focus on operational efficiency aim to ensure self-sustainability until Q3 2024 without additional capital raises.
Progress in innovative therapies like CAR-Tregs and AAV capsid evolution positions Sangamo well for advancements in genomic medicine for neurological disorders.
Exploration of partnerships and monetization opportunities present avenues for growth and strategic advancement in Sangamo's therapeutic programs.

Sangamo Therapeutics excels in neurology advancements and financial stability

Sangamo Therapeutics made significant strides in neurology programs, financial stability, and technology advancements, positioning the company for future growth
Challenges in clinical trial navigation and funding require strategic planning, while opportunities in collaborations and partnerships offer avenues for expansion
Overall, Sangamo's focus on innovation, cost efficiency, and strategic collaborations bode well for its continued success in the neurology and gene therapy space

Sangamo Therapeutics reports positive trial results and lucrative collaborations

Sangamo Therapeutics showcased strong performance in their pipeline with positive trial results and progress in the Fabry disease program.
The company's collaboration agreements and innovative technologies position them well for future growth and revenue generation.
While facing challenges in manufacturing and commercialization, Sangamo has significant opportunities in advancing genomic medicines and expanding therapeutic applications.

Sangamo Therapeutics excels in Q3, secures key partnerships and milestones

Sangamo Therapeutics demonstrated strong performance in Q3 2024, with notable advancements in key programs and financial stability.
The company's strategic partnerships, licensing agreements, and regulatory progress position it well for future growth and commercial success.
While facing funding challenges and regulatory timelines, Sangamo has opportunities to expand its pipeline, address unmet medical needs, and drive innovation in the biopharmaceutical space.
Overall, Sangamo's progress in multiple programs and ongoing discussions for collaborations underscore its commitment to delivering innovative therapies to patients in need.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Investors didn't like the preliminary results from an early-stage study.

Why Sangamo Therapeutics Stock Sank Today

BioMarin Pharmaceutical

uniQure

Sarepta Therapeutics

Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.

4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal

Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session

Editas Medicine

These gene-editing trailblazers continue advancing exciting new approaches to treating inherited diseases.

Better Buy: Editas Medicine or Sangamo Therapeutics?

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript

The gene-editing sector has a bright future ahead, but does that make every company in that market a buy?

Should Investors Buy or Sell Sangamo Therapeutics Right Now?

Clinical program SB-525 is in the process of advancing to a registrational Phase 3. Partner Pfizer has accelerated a lead-in study by leveraging their Spark hemophilia B trial.

Sangamo: Lead Gene Therapy Program Moving Into Phase 3

Sangamo Therapeutics (SGMO) CEO Sandy Macrae on Q2 2019 Results - Earnings Call Transcript

Pipeline progress was the big story in Q2 for this clinical-stage biotech.

What You'll Want to Know About Sangamo Therapeutics' Q2 Results

Pfizer

Sangamo Therapeutics reports positive results from its phase 1/2 open-label study using SB-525 to treat patients with Hemophilia A.

Sangamo's Hemophilia A Results Light A Spark And Push Program Into Pfizer's Hands

The biotech's gene therapy to treat hemophilia A looks promising.

Here's Why Sangamo Therapeutics Jumped 23% in June

Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.

Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)

Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study

Shares of Sangamo Therapeutics rose 1.1% after the gene-editing specialist and partner Pfizer presented encouraging results from a clinical trial of its hemophilia A treatment.

Sangamo reports progress treating hemophilia

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) made a handy gain to start out the week after the firm, in conjunction with Pfizer Inc.

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

In the latest Sangamo Therapeutics news, SGMO stock is gaining after the company's hemophilia A gene therapy study yielded positive results.

Sangamo Therapeutics Stock Surges on Gene Therapy Study

Results released late on Friday gave investors a reason to cheer.

Here's Why Sangamo Therapeutics Is Surging Today

Shares of Sangamo Therapeutics Inc. are higher by 7.6% Monday afternoon.

Why Is Sangamo Therapeutics Moving?

Sangamo Therapeutics stock popped Monday after the biotech company unveiled promising results for its Pfizer-partnered gene therapy in hemophilia A treatment. Sangamo stock jumped 13%.

Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals

SGMO has a seasonal trend where the share price jumps significantly on Q2 results.

Sangamo Therapeutics, Inc.: Upcoming News And Q2 Results Will Send The Stock Soaring

Investors need to pay close attention to Sangamo (SGMO) stock based on the movements in the options market lately.

Implied Volatility Surging for Sangamo (SGMO) Stock Options

CRISPR Therapeutics

Vertex Pharmaceuticals

Due to its stellar CRISPR/Cas9 platform, CRISPR Therapeutics is able to expand its collaborative relationship with the pharmaceutical elite, Vertex.

Crispr: Vertex Doubled Down On The Reigning Champion CRISPR/Cas9

The biopharma announced first-quarter 2019 operating results.

Here's Why Sangamo Therapeutics Fell as Much as 13.6% Today

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2019 Results - Earnings Call Transcript

The biotech's revenue fell. But it still managed to beat the consensus Wall Street earnings estimate.

News for Sangamo Therapeutics Stock (SGMO)